Table 2

Prevalence (or CI 95%) of AHT in patients with ERA (ESPOIR) and ESpA (DESIR) compared with the French general population in 2006–2008

GenderAge groupsFrench general populationESPOIR
Patients with ERA
DESIR
Patients with ESpA
NPrevalence (95% CI) (%)N95% CI (%)N95% CI (%)
Men18–3452.16 (0.80 to 5.25)00 to 21.8820.18 to 4.07
35–4463.66 (1.50 to 8.15)00 to 14.1384.98 to 20.22
45–542411.32 (7.53 to 16.56)99.65 to 33.7367.39 to 35.17
55–642417.78 (11.90 to 25.50)1924.47 to 51.94
65–743132.29 (23.31 to 42.71)512.99 to 61.31
Women18–3420.53 (0.09 to 2.12)10.06 to 6.8330.42 to 5.02
35–4441.52 (0.49 to 4.11)51.84 to 11.7272.72 to 12.69
45–5492.39 (1.17 to 4.75)197.49 to 18.1777.00 to 30.07
55–642912.55 (8.70 to 17.69)5228.19 to 44.29
65–743820.65 (15.19 to 27.36)1530.56 to 64.67
Total1727.58 (6.54 to 8.77)12518.14 (15.37 to 21.27)335.08 (3.57 to 7.14)
  • N, number with a diagnosis of AHT in each gender and age group.

  • AHT, arterial hypertension; DESIR, Devenir des Spondylarthropathies Indifférenciées Récentes; ERA, early rheumatoid arthritis; ESpA, early axial spondyloarthritis; ESPOIR, Etude et Suivi des Polyarthrites Indifférenciées Récentes.